Prurigo NodularisPhase 2NCT03816891
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
A Phase 2 study testing Vixarelimab in people with Prurigo Nodularis and Pruritis, run by Genentech, Inc. at 86 sites in 13 countries.
Trial summary
Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Prurigo Nodularis, Pruritis
- What is being tested?
- Vixarelimab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 240 participants
- Where
- 86 sitesin 13 countries
- Study dates
- 11 Mar 2019to 24 Aug 2023
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Inclusion Criteria (apply to both Phase 2a and Phase 2b unless otherwise specified):
- Male or female aged 18 to 75 years (Phase 2a), 18 to 80 years (Phase 2b)
- Have clinical diagnosis of prurigo nodularis for at least 6 months
- Have at least 10 nodules (Phase 2a), 20 nodules (Phase 2b) at the Screening Visit and Day 1
- Moderate to severe pruritus (Phase 2a); severe pruritus (Phase 2b)
- Female subjects of childbearing potential must have a negative pregnancy test, be nonlactating, and having agreed to use a highly effective method of contraception, as specified in the protocol, from the Screening Visit until 16 weeks after final study drug administration
- Able to comprehend and willing to sign an Informed Consent Form and able to abide by the study restrictions and comply with all study procedures for the duration of the study
Exclusion Criteria (apply to both Phase 2a and Phase 2b unless otherwise specified):
- Use of prohibited medications within the indicated timeframe from Day 1
- Is currently using medication known to cause pruritus
- Presence of any inflammatory, pruritic, and/or fibrotic skin condition other than moderate to severe prurigo nodularis or atopic dermatitis unless approved by the Sponsor
- Laboratory abnormalities that fall outside the windows specified in the protocol at the Screening Visit
- Has an active infection, including skin infection
- Any medical or psychiatric condition which, in the opinion of the Investigator or the Sponsor, may place the subject at increased risk as a result of study participation, interfere with study participation or study assessments, affect compliance with study requirements, or complicate interpretation of study results
Trial locations and contacts
86 sites in 13 countries.
86 sites in 13 countries
United States40 sites
ALLCUTIS Research, LLC
Beverly, Massachusetts, 01915
Colorado Center for Dermatology, PLLC
Centennial, Colorado, 80111
Medical University of South Carolina, Department of Dermatology and Dermatological Surgery
Charleston, South Carolina, 29425
Michigan Center for Skin Care Research
Clinton Township, Michigan, 48038
Wright State Physicians
Fairborn, Ohio, 45324
Hamzavi Dermatology
Fort Gratiot, Michigan, 48059
Rybear, Inc.
Fort Lauderdale, Florida, 33316
First OC Dermatology
Fountain Valley, California, 92708
Center for Dermatology Clinical Research, Inc.
Fremont, California, 94538
University of Florida, Department of Dermatology
Gainesville, Florida, 32610
Olympian Clinical Research
Largo, Florida, 33770
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Dermatology Research Associates
Los Angeles, California, 90045
Wallace Medical Group, Inc.
Los Angeles, California, 90056
DS Research
Louisville, Kentucky, 40241
ActivMed Practices & Research, Inc.
Methuen, Massachusetts, 01844
University of Miami Itch Center
Miami, Florida, 33136
DS Research
New Albany, Indiana, 47150
Bobby Buka MD, PC
New York, New York, 10012
Velocity Clinical Research - North Hollywood
North Hollywood, California, 91606
Skin Specialists, PC
Omaha, Nebraska, 68144
Riverchase Dermatology
Pembroke Pines, Florida, 33028
Austin Institute for Clinical Research, Inc.
Pflugerville, Texas, 78660
Paddington Testing Co., Inc.
Philadelphia, Pennsylvania, 19103
Arizona Research Center
Phoenix, Arizona, 85053
University of Rochester Dermatology at College Town
Rochester, New York, 14620
Progressive Clinical Research, PA
San Antonio, Texas, 78213
Advanced Medical Research PC
Sandy Springs, Georgia, 30328
Investigate MD, LLC
Scottsdale, Arizona, 85255
Dermatology Specialists of Spokane
Spokane, Washington, 99202
Olympian Clinical Research
St. Petersburg, Florida, 33709
Advanced Clinical Research Institute
Tampa, Florida, 33607
Palm Harbor Dermatology
Tampa, Florida, 33609
Olympian Clinical Research
Tampa, Florida, 33614
Alliance Clinical Research of Tampa
Tampa, Florida, 33615
Somerset Skin Centre
Troy, Michigan, 48084
Grekin Skin Institute
Warren, Michigan, 08088
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, 20037
Integrated Clinical Research
West Palm Beach, Florida, 33406
Canada8 sites
SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, L4M 7G1
Stratica Medical
Edmonton, Alberta, T5K 1X3
Alberta DermaSurgery Centre
Edmonton, Alberta, T6G 1C3
Brunswick Dermatology Center
Fredericton, New Brunswick, E3B 1G9
DermEffects
London, Ontario, N6H 5L5
Lynderm Research Inc.
Markham, Ontario, L3P 1X2
Central Alberta Research Clinic (CARe Clinic)
Red Deer, Alberta, T4N6V7
Drc Angélique Gagné-Henley MD Inc.
Saint-Jérôme, Quebec, J7Z 7E2
Germany8 sites
Fachklinik Bad Bentheim
Bad Bentheim, Lower Saxony, 48455
Klinikum Bielefeld Rosenhöhe
Bielefeld, North Rhine-Westphalia, 33647
University Hospital Dresden
Dresden, 01307
Studienzentrale Entzündliche Hauterkrankungen
Erlangen, 91054
George-August-Universität Göttingen
Göttingen, 37075
University Hospital Muenster, Department of Dermatology
Münster, 48149
Eberhard-Karls-University
Tübingen, 72076
Hautarztpraxis Dr. Hoffmann
Witten, 58453
Australia4 sites
Premier Specialists Pty Ltd
Kogarah, New South Wales, 2217
St. George Dermatology & Skin Cancer Centre
Kogarah, New South Wales, 2217
The Royal Melbourne Hospital
Parkville, Victoria, 3050
Veracity Clinical Research
Woolloongabba, Queensland, 4102
South Korea4 sites
The Catholic University of Korea, Incheon St. Mary's Hospital
Incheon, 21431
Seoul National University Hospital
Seoul, 03080
Severance Hospital, Yonsei University Health System
Seoul, 03722
Asan Medical Center
Seoul, 05505
Taiwan4 sites
Taipei Medical University Shuang Ho Hospital, Ministry of Health and Welfare
New Taipei City, 23561
National Taiwan University Hospital
Taipei, 10002
Taipei Veterans General Hospital
Taipei, 11217
Chang Gung Memorial Hospital
Taoyuan City, 333
United Kingdom4 sites
Royal Infirmary of Edinburgh at Little France
Edinburgh, EH16 4SA
Barts Health NHS Trust, Whipps Cross Hospital
Leytonstone, E11 1NR
Broadgreen Hospital
Liverpool, L14 3AB
University Hospital Southampton NHS Foundation Trust
Southampton, SO16 6YD
France3 sites
Hôpital Saint André - CHU de Bordeaux
Bordeaux, 33075
Hôpital Morvan - CHU Brest
Brest, 29609
CHU Nantes - Service de Dermatologie
Nantes, 44093
Poland3 sites
Grażyna Pulka Centrum Medyczne All-Med
Krakow, 30-033
Kliniczny Szpital Wojewódzki Nr 1 im. Fryderyka Chopina w Rzeszowie, Klinika Dermatologii
Rzeszów, 35-055
Kyclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
Wroclaw, 50-367
Austria2 sites
Medical University of Graz
Graz, 8036
Medical University of Vienna
Vienna, 1090
Belgium2 sites
Cliniques Universitaires Saint-Luc (UCL St-Luc)
Brussels, 1200
CHU de Liège
Liège, 4000
Italy2 sites
Asst Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Brescia, 25123
A.O.U. Policlinico Vittorio Emanuele
Catania, Sicily, 95123
About this study
Official title: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis
Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN).
Read the detailed description
This is a Phase 2a/b randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK and immunogenicity of Vixarelimab administered subcutaneously (SC) in subjects with prurigo nodularis experiencing pruritus.
Phase 2a portion:
Forty-nine subjects with moderate to severe PN experiencing moderate to severe pruritus are treated in the Phase 2a portion of the study. At Baseline, subjects are randomized 1:1 to receive double-blind (DBL) vixarelimab or placebo: vixarelimab 720 mg loading dose followed by 360 mg every week; placebo loading dose followed by placebo every week. The treatment period is 8 weeks or 16 weeks (treatment duration was reduced from 16 weeks to 8 weeks in a protocol amendment [Protocol Version 3]).
Phase 2b portion:
The Phase 2b study consists of a 4-week Screening Period and a 16-week Double-Blind Period, followed by a 36-week Open-Label-Extension (OLE) Period. Approximately 180 subjects with PN, experiencing severe pruritus, are randomized (at 1:1:1:1 ratio) into one of 4 arms (3 active arms and one placebo arm). A total of 4 doses of study drug are administered during the Double-Blind Period to measure the efficacy, safety, and PK of Vixarelimab. After the Double-Blind Period, all subjects have the option to receive vixarelimab during the OLE Period to evaluate the long-term safety and PK.
- Conditions
- Prurigo Nodularis, Pruritis
- Being tested
- Vixarelimab, Placebo
- Medical subject headings
- Pruritus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VixarelimabDrug
Also called KPL-716, RG6536
solution for injection
PlaceboDrug
solution for injection
| Study group | Role | What they receive |
|---|---|---|
| Phase 2a - Vixarelimab 360 mg SC Weekly (QW) | Experimental | Vixarelimab 720 mg loading dose followed by 360 mg weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2) Receives: Drug: Vixarelimab |
| Phase 2a - Placebo SC QW | Placebo comparator | Placebo loading dose followed by placebo weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2) Receives: Drug: Placebo |
| Phase 2b - Vixarelimab 540 mg SC Every 4 Weeks (Q4W; DBL) | Experimental | Vixarelimab 540 mg SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period Receives: Drug: Vixarelimab |
| Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL) | Experimental | Vixarelimab 360 mg SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period Receives: Drug: Vixarelimab |
| Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL) | Experimental | Vixarelimab 120 mg SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period Receives: Drug: Vixarelimab |
| Phase 2b - Placebo SC, Q4W (DBL) | Placebo comparator | Placebo SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period Receives: Drug: Placebo |
| Phase 2b - Vixarelimab 360 mg SC, Every 2 Weeks (Q2W; OLE) | Experimental | Vixarelimab 360 mg SC, every 2 weeks for 36 weeks during Open Label Extension Receives: Drug: Vixarelimab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score
Participants rated pruritus daily on the Worst Itch [pruritis] Numeric Rating Scale (WI-NRS: 0=no pruritus; 10=worst imaginable pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: at Week 8 (Phase 2a); at Week 16 (Phase 2b)
Secondary outcomes (38)
Phase 2a: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS at Week 8
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).
Measured: Baseline, Week 8
Phase 2a: Percent Change From Baseline in Pruritus Visual Analog Scale (VAS) at Week 8
At every visit, participants rated the intensity of their average pruritus over previous 3 days on VAS 0-10 line scale (0=no pruritis, 10=worst imaginable pruritis)
Measured: Baseline, Week 8
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over Time
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Percent Change From Baseline in Weekly Average of WI-NRS Over Time
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Change From Baseline in Pruritis Visual Analog Scale (VAS) Over Time
Participants rated intensity of their average pruritus over previous 3 days on VAS 0-10 line scale (0=no pruritis, 10=worst imaginable pruritis)
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 24
Phase 2a: Percent Change From Baseline in Pruritis Visual Analog Scale (VAS) Over Time
Participants rated intensity of their average pruritus over previous 3 days on VAS 0-10 line scale (0=no pruritis, 10=worst imaginable pruritis). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 24
Phase 2a: Change From Baseline in 5-D Pruritus Total Score Over Time
Administered every 2 visits, the 5-D Pruritus Scale evaluates pruritus in 5 domains: duration, degree, direction, disability and distribution. The scores from each domain are added together to obtain a total 5-D score ranging from 5 (no pruritus) to 25 (most severe pruritus).
Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Percent Change From Baseline in 5-D Pruritus Total Score Over Time
Administered every 2 visits, the 5-D Pruritus Scale evaluates pruritus in five domains: duration, degree, direction, disability and distribution. The scores from each domain are added together to obtain a total 5-D score ranging from 5 (no pruritus) to 25 (most severe pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS Over Time
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Change From Baseline in Sleep Loss VAS Over Time
Participants rated intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness).
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24
Phase 2a: Percent Change From Baseline in Sleep Loss VAS Over Time
Participants rated intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24
Phase 2a: Change From Baseline in Weekly Average of Difficulty Falling Asleep NRS Over Time
Participants rate difficulty falling asleep daily on Numerical Rating Scale (0=no difficulty, 10=extremely difficult).
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Percent Change From Baseline in Weekly Average of Difficulty Falling Asleep NRS Over Time
Participants rate difficulty falling asleep daily on Numerical Rating Scale (0=no difficulty, 10=extremely difficult). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Change From Baseline in Weekly Average of Sleep Quality NRS Over Time
Participants rated daily sleep quality on Numerical Rating Scale (0=best possible sleep, 10=worst possible sleep).
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Percent Change From Baseline in Weekly Average of Sleep Quality NRS Over Time
Participants rated daily sleep quality on Numerical Rating Scale (0=best possible sleep, 10=worst possible sleep). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Change From Baseline in Quality of Life (QoL) Measure Dermatology QoL Index (DLQI) Over Time
QoL was assessed at designated visits and includes the DLQI whereby 0=no effect on quality of life; 30= extremely large effect on QoL.
Measured: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24
Phase 2a: Percent Change From Baseline in QoL Measure DLQI Over Time
QoL was assessed at designated visits and includes the DLQI whereby 0=no effect on quality of life; 30= extremely large effect on QoL.
Measured: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24
Phase 2a: Change From Baseline in QoL Measure Itchy Quality of Life (ItchyQoL) Over Time
ItchyQoL focuses on impact of pruritus on daily activities and on the level of psychological stress. It contains 22 items. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered). The recall period in ItchyQoL is the past week. The ItchyQoL total score is defined as the sum of all 22-items scores. Total scores can be classified as little (0-30), mild (31-50), moderate (51-80), and severe (81-110).
Measured: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24
Phase 2a: Percent Change From Baseline in QoL Measure Itchy QoL Over Time
ItchyQoL focuses on impact of pruritus on daily activities and on the level of psychological stress. It contains 22 items. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered). The recall period in ItchyQoL is the past week. The ItchyQoL total score is defined as the sum of all 22-items scores. Total scores can be classified as little (0-30), mild (31-50), moderate (51-80), and severe (81-110). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24
Phase 2a: Change From Baseline in Prurigo Nodularis Nodule Assessment Tool (PN-NAT) Over Time: Number of Nodules Over the Whole Body Score
PN-NAT, assessed at designated visits, is a novel exploratory tool for the evaluation of disease severity based on estimate of the number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriation over the whole body, distribution of nodules, exact number of nodules in the representative area. The first three components (number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriations over the whole body) were analyzed as secondary endpoints. For the Number of Nodules over the Whole Body score: 0=0 nodules; 1=1 to 9 nodules; 2=10 to 50 nodules; and 3=more than 50 nodules. A higher score indicates worse disease.
Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Change From Baseline in PN-NAT Over Time: Estimate of Hardness of Nodules Over the Whole Body
PN-NAT, assessed at designated visits, is a novel exploratory tool for the evaluation of disease severity based on estimate of the number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriation over the whole body, distribution of nodules, exact number of nodules in the representative area. The first three components (number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriations over the whole body) were analyzed as secondary endpoints. For the Estimate of Hardness of Nodules Over the Whole Body score: 0=No nodules are hard; 1=Up to one-third of nodules are hard; 2=One-third to two-thirds of nodules are hard; and 3=More than two-thirds of nodules are hard. A higher score indicates worse disease.
Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Change From Baseline in PN-NAT Over Time: Extent of Excoriations Over the Whole Body
PN-NAT, assessed at designated visits, is a novel exploratory tool for the evaluation of disease severity based on estimate of the number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriation over the whole body, distribution of nodules, exact number of nodules in the representative area. The first three components (number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriations over the whole body) were analyzed as secondary endpoints. For the Extent of Excoriations over the Whole Body score: 0=No nodules are excoriated; 1=Up to one-third of nodules are excoriated; 2=One-third to two-thirds of nodules are excoriated; and 3=More than two-thirds of nodules are excoriated. A higher score indicates worse disease.
Measured: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Percentage of Participants With Improvement in Prurigo Nodularis Investigator Global Assessment (PN-IGA) by 2 Categories Over Time
PN-IGA, assessed at designated visits, is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the presence/absence of nodules and the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease).
Measured: Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2b: Percentage of Participants Achieving at Least a 6-Point Reduction From Baseline in Weekly Average WI-NRS at Week 16
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (0=no pruritus; 10=worst imaginable pruritus).
Measured: Baseline, Week 16
Phase 2b: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS at Week 16
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (0=no pruritus; 10=worst imaginable pruritus).
Measured: Baseline, Week 16
Phase 2b: Percentage of Participants Achieving a Score of 0 or 1 in PN-IGA at Week 16
PN-IGA, assessed at designated visits, is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the presence/absence of nodules and the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease); 0 (clear) indicates no nodules and 1 (almost clear) indicates nodules are present, few of the nodules are moderately raised.
Measured: Week 16
Phase 2b: Change From Baseline in Weekly Average of WI-NRS Over Time
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 1 through 52
Phase 2b: Percent Change From Baseline in Weekly Average of WI-NRS Over Time
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 1 through 52
Phase 2b: Percentage of Participants Achieving at Least a 6-Point Reduction From Baseline in Weekly Average WI-NRS Over Time
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).
Measured: Baseline, Weeks 1 through 52
Phase 2b: Percentage of Participants Achieving at Least a 4-Point Reduction From Baseline in Weekly Average WI-NRS Over Time
Participants rated pruritus daily on the Worst Itch [pruritis]-Numeric Rating Scale (WI-NRS; 0=no pruritus; 10=worst imaginable pruritus).
Measured: Baseline, Weeks 1 through 52
Phase 2b: Percentage of Participants Achieving 0 or 1 in PN-IGA Over Time
PN-IGA is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the presence/absence of nodules and the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease); 0 (clear) indicates no nodules and 1 (almost clear) indicates nodules are present, few of the nodules are moderately raised.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percentage of Participants With at Least 2-Point Improvement From Baseline in PN-IGA Over Time
PN-IGA is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease).
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percentage of Participants Achieving 0 (Clear) or 1 (Almost Clear) in Investigator's Global Assessment for Prurigo Nodularis-Stage (IGA-CNPG-S) Over Time
IGA-CNPG-S is a novel tool for the investigator assessment of PN disease severity based on the number of palpable nodules and utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe); 0 (clear) indicates no nodules and 1 (almost clear) indicates rare palpable pruriginous nodules (approximately 1-5 nodules). A score is assigned based on the appearance of the disease at the time of the evaluation without referring to the baseline state.
Measured: Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percentage of Participants With at Least 2-point Improvement From Baseline in IGA-CNPG-S Over Time
IGA-CNPG-S, administered at designated visits, is a novel tool for the investigator assessment of PN disease severity based on the number of palpable nodules and utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe). A score is assigned based on the appearance of the disease at the time of the evaluation without referring to the baseline state.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Change From Baseline in Weekly Average of Sleep Loss VAS Over Time
Participants rated intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness). A score was set to missing after a participant received prohibited/rescue medication that potentially impact efficacy analyses prior to Week 16, and the participant's worst post baseline observation before the time of the medication usage was carried forward (WOCF) to impute missing endpoint value (for participants whose postbaseline values were all missing, the baseline was used to impute). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percent Change From Baseline in Weekly Average of Sleep Loss VAS Over Time
Participants rated intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness). A score was set to missing after a participant received prohibited/rescue medication that potentially impact efficacy analyses prior to Week 16, and the participant's worst post baseline observation before the time of the medication usage was carried forward (WOCF) to impute missing endpoint value (for participants whose postbaseline values were all missing, the baseline was used to impute). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Change From Baseline in ItchyQoL Over Time
ItchyQoL focuses on impact of pruritus on daily activities and on the level of psychological stress. It contains 22 items. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered). The recall period in ItchyQoL is the past week. The ItchyQoL total score is defined as the sum of all 22-items scores. Total scores can be classified as little (0-30), mild (31-50), moderate (51-80), and severe (81-110). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percent Change From Baseline in ItchyQoL Over Time
ItchyQoL focuses on impact of pruritus on daily activities and on the level of psychological stress. It contains 22 items. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered). The recall period in ItchyQoL is the past week. The ItchyQoL total score is defined as the sum of all 22-items scores. Total scores can be classified as little (0-30), mild (31-50), moderate (51-80), and severe (81-110). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
Measured: Baseline, Weeks 4, 8, 12, 16, 18, 20, 32, 48, 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2019
- Study start11 Mar 2019
- Primary completion28 Dec 2022
- Study completion24 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Prurigo NodularisStudies of the same condition, open and under way.
- More trials run by Genentech, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Phase 2a: 2 arms; Phase 2b: 5 arms (4 arms during Double Blind Period and 1 arm during Open Label Extension)
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 240 participants (actual)
Sponsor and investigators
- Lead sponsor
- Genentech, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Kiniksa Pharmaceuticals, Ltd.
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Genentech, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03816891
- Sponsor's protocol ID
- KPL-716-C201
- Other IDs
- GS45044
- Status last verified
- Jan 2026
- First submitted
- 23 Jan 2019
- Last updated
- 13 Jan 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Stander S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF. Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial. JAMA Dermatol. 2026 Feb 1;162(2):133-141. doi: 10.1001/jamadermatol.2025.4950.
PubMed 41405882Ma DX, Neerumalla S, Baird A, Whitehead RA, Filip P, Tajudeen BA, Batra PS, Papagiannopoulos P. Impact of Obesity on the Structured Histopathology of Chronic Rhinosinusitis Patients. Laryngoscope. 2026 Mar;136(3):1150-1157. doi: 10.1002/lary.70177. Epub 2025 Oct 6.
PubMed 41051123Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. eCollection 2023 Mar.
PubMed 36816342
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis
- ClinicalTrials.gov ID
- NCT03816891
- Acronym / sponsor ID
- KPL-716-C201
- Conditions
- Prurigo Nodularis, Pruritis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 240 participants (actual)
- Lead sponsor
- Genentech, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Kiniksa Pharmaceuticals, Ltd.
- Study start
- 11 Mar 2019 (actual)
- Primary completion
- 28 Dec 2022 (actual)
- Study completion
- 24 Aug 2023 (actual)
- First posted
- 25 Jan 2019 (actual)
- Results
- Posted 13 Jan 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN).
Detailed description
This is a Phase 2a/b randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK and immunogenicity of Vixarelimab administered subcutaneously (SC) in subjects with prurigo nodularis experiencing pruritus.
Phase 2a portion:
Forty-nine subjects with moderate to severe PN experiencing moderate to severe pruritus are treated in the Phase 2a portion of the study. At Baseline, subjects are randomized 1:1 to receive double-blind (DBL) vixarelimab or placebo: vixarelimab 720 mg loading dose followed by 360 mg every week; placebo loading dose followed by placebo every week. The treatment period is 8 weeks or 16 weeks (treatment duration was reduced from 16 weeks to 8 weeks in a protocol amendment [Protocol Version 3]).
Phase 2b portion:
The Phase 2b study consists of a 4-week Screening Period and a 16-week Double-Blind Period, followed by a 36-week Open-Label-Extension (OLE) Period. Approximately 180 subjects with PN, experiencing severe pruritus, are randomized (at 1:1:1:1 ratio) into one of 4 arms (3 active arms and one placebo arm). A total of 4 doses of study drug are administered during the Double-Blind Period to measure the efficacy, safety, and PK of Vixarelimab. After the Double-Blind Period, all subjects have the option to receive vixarelimab during the OLE Period to evaluate the long-term safety and PK.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 7
- Model description
- Phase 2a: 2 arms; Phase 2b: 5 arms (4 arms during Double Blind Period and 1 arm during Open Label Extension)
| Arm | Type | Receives |
|---|---|---|
| Phase 2a - Vixarelimab 360 mg SC Weekly (QW) | Experimental | Drug: VixarelimabVixarelimab 720 mg loading dose followed by 360 mg weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2) |
| Phase 2a - Placebo SC QW | Placebo comparator | Drug: PlaceboPlacebo loading dose followed by placebo weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2) |
| Phase 2b - Vixarelimab 540 mg SC Every 4 Weeks (Q4W; DBL) | Experimental | Drug: VixarelimabVixarelimab 540 mg SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period |
| Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL) | Experimental | Drug: VixarelimabVixarelimab 360 mg SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period |
| Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL) | Experimental | Drug: VixarelimabVixarelimab 120 mg SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period |
| Phase 2b - Placebo SC, Q4W (DBL) | Placebo comparator | Drug: PlaceboPlacebo SC, every 4 weeks (Q4W) for 16 weeks during Double Blind Period |
| Phase 2b - Vixarelimab 360 mg SC, Every 2 Weeks (Q2W; OLE) | Experimental | Drug: VixarelimabVixarelimab 360 mg SC, every 2 weeks for 36 weeks during Open Label Extension |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VixarelimabAlso: KPL-716, RG6536solution for injection | Drug | Phase 2a - Vixarelimab 360 mg SC Weekly (QW), Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL), Phase 2b - Vixarelimab 360 mg SC, Every 2 Weeks (Q2W; OLE), Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL), Phase 2b - Vixarelimab 540 mg SC Every 4 Weeks (Q4W; DBL) |
| Placebosolution for injection | Drug | Phase 2a - Placebo SC QW, Phase 2b - Placebo SC, Q4W (DBL) |
Primary outcome
Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score
Time frame: at Week 8 (Phase 2a); at Week 16 (Phase 2b)
Participants rated pruritus daily on the Worst Itch [pruritis] Numeric Rating Scale (WI-NRS: 0=no pruritus; 10=worst imaginable pruritus). The least squares mean (LSM) and LSM difference were rounded up or down to the nearest single decimal place.
38 secondary outcomes
Phase 2a: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS at Week 8
Time frame: Baseline, Week 8
Phase 2a: Percent Change From Baseline in Pruritus Visual Analog Scale (VAS) at Week 8
Time frame: Baseline, Week 8
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Percent Change From Baseline in Weekly Average of WI-NRS Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Change From Baseline in Pruritis Visual Analog Scale (VAS) Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 24
Phase 2a: Percent Change From Baseline in Pruritis Visual Analog Scale (VAS) Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 24
Phase 2a: Change From Baseline in 5-D Pruritus Total Score Over Time
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Percent Change From Baseline in 5-D Pruritus Total Score Over Time
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Change From Baseline in Sleep Loss VAS Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24
Phase 2a: Percent Change From Baseline in Sleep Loss VAS Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24
Phase 2a: Change From Baseline in Weekly Average of Difficulty Falling Asleep NRS Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Percent Change From Baseline in Weekly Average of Difficulty Falling Asleep NRS Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Change From Baseline in Weekly Average of Sleep Quality NRS Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Percent Change From Baseline in Weekly Average of Sleep Quality NRS Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Phase 2a: Change From Baseline in Quality of Life (QoL) Measure Dermatology QoL Index (DLQI) Over Time
Time frame: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24
Phase 2a: Percent Change From Baseline in QoL Measure DLQI Over Time
Time frame: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24
Phase 2a: Change From Baseline in QoL Measure Itchy Quality of Life (ItchyQoL) Over Time
Time frame: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24
Phase 2a: Percent Change From Baseline in QoL Measure Itchy QoL Over Time
Time frame: Baseline, Weeks 2, 4, 6, 8, 12, 16, 24
Phase 2a: Change From Baseline in Prurigo Nodularis Nodule Assessment Tool (PN-NAT) Over Time: Number of Nodules Over the Whole Body Score
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Change From Baseline in PN-NAT Over Time: Estimate of Hardness of Nodules Over the Whole Body
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Change From Baseline in PN-NAT Over Time: Extent of Excoriations Over the Whole Body
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2a: Percentage of Participants With Improvement in Prurigo Nodularis Investigator Global Assessment (PN-IGA) by 2 Categories Over Time
Time frame: Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24
Phase 2b: Percentage of Participants Achieving at Least a 6-Point Reduction From Baseline in Weekly Average WI-NRS at Week 16
Time frame: Baseline, Week 16
Phase 2b: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS at Week 16
Time frame: Baseline, Week 16
Phase 2b: Percentage of Participants Achieving a Score of 0 or 1 in PN-IGA at Week 16
Time frame: Week 16
Phase 2b: Change From Baseline in Weekly Average of WI-NRS Over Time
Time frame: Baseline, Weeks 1 through 52
Phase 2b: Percent Change From Baseline in Weekly Average of WI-NRS Over Time
Time frame: Baseline, Weeks 1 through 52
Phase 2b: Percentage of Participants Achieving at Least a 6-Point Reduction From Baseline in Weekly Average WI-NRS Over Time
Time frame: Baseline, Weeks 1 through 52
Phase 2b: Percentage of Participants Achieving at Least a 4-Point Reduction From Baseline in Weekly Average WI-NRS Over Time
Time frame: Baseline, Weeks 1 through 52
Phase 2b: Percentage of Participants Achieving 0 or 1 in PN-IGA Over Time
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percentage of Participants With at Least 2-Point Improvement From Baseline in PN-IGA Over Time
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percentage of Participants Achieving 0 (Clear) or 1 (Almost Clear) in Investigator's Global Assessment for Prurigo Nodularis-Stage (IGA-CNPG-S) Over Time
Time frame: Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percentage of Participants With at Least 2-point Improvement From Baseline in IGA-CNPG-S Over Time
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Change From Baseline in Weekly Average of Sleep Loss VAS Over Time
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percent Change From Baseline in Weekly Average of Sleep Loss VAS Over Time
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Change From Baseline in ItchyQoL Over Time
Time frame: Baseline, Weeks 4, 8, 12, 16, 18, 20, 32, 48, 52
Phase 2b: Percent Change From Baseline in ItchyQoL Over Time
Time frame: Baseline, Weeks 4, 8, 12, 16, 18, 20, 32, 48, 52
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41405882Stander S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF. Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial. JAMA Dermatol. 2026 Feb 1;162(2):133-141. doi: 10.1001/jamadermatol.2025.4950.
- Derived from this study: PubMed 41051123Ma DX, Neerumalla S, Baird A, Whitehead RA, Filip P, Tajudeen BA, Batra PS, Papagiannopoulos P. Impact of Obesity on the Structured Histopathology of Chronic Rhinosinusitis Patients. Laryngoscope. 2026 Mar;136(3):1150-1157. doi: 10.1002/lary.70177. Epub 2025 Oct 6.
- Derived from this study: PubMed 36816342Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. eCollection 2023 Mar.
- Individual participant dataSharing planned: Undecided
Related trials for Prurigo Nodularis
Not yet recruitingPhase 2
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.
Prurigo Nodularis (PN)
RecruitingPhase 3
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Prurigo Nodularis
RecruitingPhase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Prurigo Nodularis (PN)
RecruitingObservational study
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
Prurigo Nodularis
Not yet recruitingPhase 2
Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
Prurigo Nodularis (PN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Genentech, Inc.
86 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Vixarelimab in people with Prurigo Nodularis and Pruritis, run by Genentech, Inc. at 86 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 86 sites in United States, Canada, Germany, Australia, South Korea and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Jan 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score (time frame: at Week 8 (Phase 2a); at Week 16 (Phase 2b)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03816891, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.